Learn more at LeadIQ.com

Insights

Acquisition Opportunity Ligand Pharmaceuticals Incorporated recently acquired Apeiron Biologics AG for $100 million, indicating potential synergies and opportunities for cross-selling and expanding product reach.

Pipeline Expansion APEIRON Biologics has ongoing Phase Ib trials for APN401 targeting solid tumors, presenting potential collaboration opportunities for pharmaceutical sales to support the development and commercialization of this novel therapy.

Strategic Partnerships Apeiron Biologics has established partnerships with companies like Domainex and Sanofi for drug development, creating potential avenues for collaborative sales efforts in advancing cancer immunotherapies and respiratory treatments.

Financial Support Despite zero listed funding, APEIRON Biologics received significant financing of $19.9 million for COVID-19 drug development and immuno-oncology projects, indicating potential investment for sales expansion and product promotion.

Market Positioning APEIRON Biologics' focus on breakthrough therapies for cancer and respiratory conditions, as well as its well-balanced product portfolio, presents a competitive edge for sales representatives targeting healthcare institutions and providers in these specialized areas.

Similar companies to APEIRON Biologics AG

APEIRON Biologics AG Tech Stack

APEIRON Biologics AG uses 8 technology products and services including W3 Total Cache, jQuery Migrate, Lightbox, and more. Explore APEIRON Biologics AG's tech stack below.

W3 Total Cache
Caching
jQuery Migrate
Javascript Libraries
Lightbox
Javascript Libraries
RSS
Miscellaneous
Debian
Operating Systems
Bootstrap
UI Frameworks
Animate.css
UI Frameworks
Apache HTTP Server
Web Servers

Media & News

APEIRON Biologics AG's Email Address Formats

APEIRON Biologics AG uses at least 1 format(s):

APEIRON Biologics AG Email Formats	Example	Percentage
First.Last@apeiron-biologics.com	John.Doe@apeiron-biologics.com	50%
First.Last@apeiron-biologics.com	John.Doe@apeiron-biologics.com	50%

Frequently Asked Questions

Where is APEIRON Biologics AG's headquarters located?

APEIRON Biologics AG's main headquarters is located at Campus-Vienna-Biocenter 5 Wien, Wien 1030 AT. The company has employees across 2 continents, including EuropeNorth America.

What is APEIRON Biologics AG's official website and social media links?

APEIRON Biologics AG's official website is apeiron-biologics.com and has social profiles on LinkedIn.

What is APEIRON Biologics AG's SIC code NAICS code?

APEIRON Biologics AG's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does APEIRON Biologics AG have currently?

As of April 2024, APEIRON Biologics AG has approximately 12 employees across 2 continents, including EuropeNorth America. Key team members include Chairman Of The Supervisory Board: M. R.Project Head Bei Apeiron Biologics: R. S.Lab Techn: S. S.. Explore APEIRON Biologics AG's employee directory with LeadIQ.

What industry does APEIRON Biologics AG belong to?

APEIRON Biologics AG operates in the Biotechnology Research industry.

What technology does APEIRON Biologics AG use?

APEIRON Biologics AG's tech stack includes W3 Total CachejQuery MigrateLightboxRSSDebianBootstrapAnimate.cssApache HTTP Server.

What is APEIRON Biologics AG's email format?

APEIRON Biologics AG's email format typically follows the pattern of . Find more APEIRON Biologics AG email formats with LeadIQ.

When was APEIRON Biologics AG founded?

APEIRON Biologics AG was founded in 2003.

APEIRON Biologics AG

APEIRON Biologics AG

Biotechnology ResearchWien, Austria11-50 Employees

APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies.  

Our company has a well balanced portfolio with one product on the market and several promising products from clinical to pre-clinical stages. As for the product on the market, APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients. We out-licensed Qarziba® globally to EUSA Pharma Ltd, for which it holds exclusive rights to this product.

APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. Our development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.

Company Overview

Headquarters: Campus-Vienna-Biocenter 5 Wien, Wien 1030 AT
Website: apeiron-biologics.com
SIC Code: 8731 - Commercial Physical and Biological Research
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2003
Employees: 11-50

Media & News

Funding & Financials

Funding & Financials

Company Leadership

M. R.
Chairman Of The Supervisory Board
✕
Access Insights for APEIRON Biologics AG and Millions of Other Companies
Sign up for full access to APEIRON Biologics AG information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for APEIRON Biologics AG and Millions of Other Companies
Sign up for full access to APEIRON Biologics AG information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
R. S.
Project Head Bei Apeiron Biologics
✕
Access Insights for APEIRON Biologics AG and Millions of Other Companies
Sign up for full access to APEIRON Biologics AG information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for APEIRON Biologics AG and Millions of Other Companies
Sign up for full access to APEIRON Biologics AG information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
S. S.
Lab Techn
✕
Access Insights for APEIRON Biologics AG and Millions of Other Companies
Sign up for full access to APEIRON Biologics AG information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for APEIRON Biologics AG and Millions of Other Companies
Sign up for full access to APEIRON Biologics AG information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.